Maria Irina Brumboiu, Edina Iuga, Andreea Ivanciuc, Irina Iaru, Alexandru Durla-Pașca, Pavel Șchiopu, Adrian Gabriel Pană
Background. Pulmonary superinfections increase the mortality risk among COVID-19 patients, highlighting the need for enhanced understanding to enable early and accurate diagnosis. Methods. We present the case of a patient, a 76-year-old man, hospitalized for a severe form of COVID-19, with a ground-glass pneumonia, involving 40-45% of lung surfaces. Results. In evolution, the clinical condition worsened, presenting leukocytosis with neutrophilia, imaging towards resorption, and computer tomography images showing the appearance of pulmonary condensations in the right lower lobe, the posterior portion of the left lower lobe and pleural collections. Carbapenemase-producing Klebsiella pneumoniae was isolated from the tracheal aspirate, and the real-time polymerase chain reaction test was positive for Klebsiella pneumoniae and Legionella pneumophila. The investigations that were carried out allowed us to establish the coinfections as a probable case of Legionnaire's disease and a ventilator-associated pneumonia with Klebsiella pneumoniae. Conclusions. The case analysis revealed that rare pneumonias may remain undiagnosed, and coinfections may be conditioned by pathophysiological factors or components of COVID-19 critical form treatment. Enhanced understanding of these aspects in clinical practice may contribute to reducing mortality risk in COVID-19 patients.
{"title":"<i>Legionella pneumophila</i>-<i>Klebsiella pneumoniae</i> Pulmonary Coinfection in a COVID-19 Patient: Case Report.","authors":"Maria Irina Brumboiu, Edina Iuga, Andreea Ivanciuc, Irina Iaru, Alexandru Durla-Pașca, Pavel Șchiopu, Adrian Gabriel Pană","doi":"10.3390/idr16060085","DOIUrl":"10.3390/idr16060085","url":null,"abstract":"<p><p><b>Background.</b> Pulmonary superinfections increase the mortality risk among COVID-19 patients, highlighting the need for enhanced understanding to enable early and accurate diagnosis. <b>Methods.</b> We present the case of a patient, a 76-year-old man, hospitalized for a severe form of COVID-19, with a ground-glass pneumonia, involving 40-45% of lung surfaces. <b>Results.</b> In evolution, the clinical condition worsened, presenting leukocytosis with neutrophilia, imaging towards resorption, and computer tomography images showing the appearance of pulmonary condensations in the right lower lobe, the posterior portion of the left lower lobe and pleural collections. Carbapenemase-producing <i>Klebsiella pneumoniae</i> was isolated from the tracheal aspirate, and the real-time polymerase chain reaction test was positive for <i>Klebsiella pneumoniae</i> and <i>Legionella pneumophila</i>. The investigations that were carried out allowed us to establish the coinfections as a probable case of Legionnaire's disease and a ventilator-associated pneumonia with <i>Klebsiella pneumoniae</i>. <b>Conclusions.</b> The case analysis revealed that rare pneumonias may remain undiagnosed, and coinfections may be conditioned by pathophysiological factors or components of COVID-19 critical form treatment. Enhanced understanding of these aspects in clinical practice may contribute to reducing mortality risk in COVID-19 patients.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 6","pages":"1055-1063"},"PeriodicalIF":3.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mihaela Pertea, Stefana Luca, Raluca Tatar, Bogdan Huzum, Mihai Ciofu, Vladimir Poroch, Dragos Octavian Palade, Daniela Vrinceanu, Mihail Balan, Oxana Madalina Grosu
(1) Background: Necrotizing fasciitis is known as a severe condition with a high risk of mortality, placing it among the most feared infections. In most cases, it has a polymicrobial etiology (type 1), requiring complex treatment that is continuously adapted to the evolving microbiological status. The facial localization of the disease is rare, fulminant progressing, and is often life-threatening. (2) Methods: We present the case of a patient with multiple comorbidities who, following trauma to the nasal dorsum, developed a wound with a rapid and severe progression to extensive bilateral periorbital necrosis. This was accompanied by a dramatic deterioration in their general condition, a polymicrobial biological status, and fluctuating progression despite instituted treatment (both medical and surgical). (3) Results: The patient required multiple surgical interventions by multidisciplinary teams (plastic surgery; ear, nose, and throat specialist (ENT); maxillofacial surgery; and ophthalmology), experiencing periods of a severe, life-threatening general condition, necessitating prolonged orotracheal intubation. Wounds with fluctuating progression, extensive skin necrosis, and significant post-excisional soft tissue defects required skin graft coverage. The result meant a saved life and functional and aesthetic sequelae at the level of the face. (4) Conclusions: Necrotizing fasciitis of the face is a rare and severe disease that must be recognized early and treated appropriately by a multidisciplinary team to save the patient's life and minimize the resulting functional and aesthetic sequelae.
{"title":"Multidisciplinary Approach in Rare, Fulminant-Progressing, and Life-Threatening Facial Necrotizing Fasciitis.","authors":"Mihaela Pertea, Stefana Luca, Raluca Tatar, Bogdan Huzum, Mihai Ciofu, Vladimir Poroch, Dragos Octavian Palade, Daniela Vrinceanu, Mihail Balan, Oxana Madalina Grosu","doi":"10.3390/idr16060084","DOIUrl":"10.3390/idr16060084","url":null,"abstract":"<p><p>(1) Background: Necrotizing fasciitis is known as a severe condition with a high risk of mortality, placing it among the most feared infections. In most cases, it has a polymicrobial etiology (type 1), requiring complex treatment that is continuously adapted to the evolving microbiological status. The facial localization of the disease is rare, fulminant progressing, and is often life-threatening. (2) Methods: We present the case of a patient with multiple comorbidities who, following trauma to the nasal dorsum, developed a wound with a rapid and severe progression to extensive bilateral periorbital necrosis. This was accompanied by a dramatic deterioration in their general condition, a polymicrobial biological status, and fluctuating progression despite instituted treatment (both medical and surgical). (3) Results: The patient required multiple surgical interventions by multidisciplinary teams (plastic surgery; ear, nose, and throat specialist (ENT); maxillofacial surgery; and ophthalmology), experiencing periods of a severe, life-threatening general condition, necessitating prolonged orotracheal intubation. Wounds with fluctuating progression, extensive skin necrosis, and significant post-excisional soft tissue defects required skin graft coverage. The result meant a saved life and functional and aesthetic sequelae at the level of the face. (4) Conclusions: Necrotizing fasciitis of the face is a rare and severe disease that must be recognized early and treated appropriately by a multidisciplinary team to save the patient's life and minimize the resulting functional and aesthetic sequelae.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 6","pages":"1045-1054"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ziv Rosman, Yasmin Maor, Iris Zohar, Gingy Ronen Balmor, Miri Schamroth Pravda, Adam Lee Goldstein, Milena Tocut, Arie Soroksky
Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. Objectives: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. Methods: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. Results: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. Conclusions: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.
{"title":"Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study-Preliminary Results.","authors":"Ziv Rosman, Yasmin Maor, Iris Zohar, Gingy Ronen Balmor, Miri Schamroth Pravda, Adam Lee Goldstein, Milena Tocut, Arie Soroksky","doi":"10.3390/idr16060083","DOIUrl":"10.3390/idr16060083","url":null,"abstract":"<p><p>Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. <b>Objectives</b>: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. <b>Methods</b>: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. <b>Results</b>: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. <b>Conclusions</b>: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 6","pages":"1036-1044"},"PeriodicalIF":3.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kavita Prasad, John Ceremsak, Jean-Nicolas Gallant, Hannah G Kay, Erin B Gettler, Benjamin R Campbell, Catherine R Carlile, Byron F Stephens, Sarah L Rohde, Patty W Wright, Christina T Fiske
(1) Background/Objectives: Delayed esophageal perforation following anterior cervical (spine) discectomy and fusion (ACDF) is rare but can lead to serious infectious complications. The treatment usually involves hardware explanation and prolonged intravenous antibiotics; however, there are scarce reports about the microbiology of these infections and corresponding targeted therapy. (2) Methods: Patients diagnosed or treated for delayed esophageal perforation after anterior cervical fusion between 2000-2020 at a tertiary medical center were studied. (3) Results: Seven patients with delayed esophageal perforation following ACDF were identified. The most common bacteria isolated included Streptococcus, Haemophilus, and Mycobacterium species. The cultures from five patients grew fungal species, including Candida albicans and C. glabrata. All the patients received several weeks of broad-spectrum antibiotics, and, notably, 5/7 patients received antifungal therapy targeting Candida. (4) Conclusions: Although the incidence of delayed esophageal perforation following ACDF is low, providers should remain aware of this entity due to the serious infectious complications. Most infections are polymicrobial in nature, and providers should consider empiric antifungal coverage specifically targeting Candida species when treating patients with this complication.
{"title":"Consideration of Antifungal Coverage in Treating Infections Related to Delayed Esophageal Perforation from Anterior Cervical Spine Hardware.","authors":"Kavita Prasad, John Ceremsak, Jean-Nicolas Gallant, Hannah G Kay, Erin B Gettler, Benjamin R Campbell, Catherine R Carlile, Byron F Stephens, Sarah L Rohde, Patty W Wright, Christina T Fiske","doi":"10.3390/idr16060082","DOIUrl":"https://doi.org/10.3390/idr16060082","url":null,"abstract":"<p><p>(1) Background/Objectives: Delayed esophageal perforation following anterior cervical (spine) discectomy and fusion (ACDF) is rare but can lead to serious infectious complications. The treatment usually involves hardware explanation and prolonged intravenous antibiotics; however, there are scarce reports about the microbiology of these infections and corresponding targeted therapy. (2) Methods: Patients diagnosed or treated for delayed esophageal perforation after anterior cervical fusion between 2000-2020 at a tertiary medical center were studied. (3) Results: Seven patients with delayed esophageal perforation following ACDF were identified. The most common bacteria isolated included <i>Streptococcus</i>, <i>Haemophilus</i>, and <i>Mycobacterium</i> species. The cultures from five patients grew fungal species, including <i>Candida albicans</i> and <i>C. glabrata</i>. All the patients received several weeks of broad-spectrum antibiotics, and, notably, 5/7 patients received antifungal therapy targeting <i>Candida</i>. (4) Conclusions: Although the incidence of delayed esophageal perforation following ACDF is low, providers should remain aware of this entity due to the serious infectious complications. Most infections are polymicrobial in nature, and providers should consider empiric antifungal coverage specifically targeting <i>Candida</i> species when treating patients with this complication.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 6","pages":"1030-1035"},"PeriodicalIF":3.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Variations in the fusion (F) protein of respiratory syncytial virus (RSV) with main antigenic sites I-V and Ø may affect the development of RSV vaccines and therapies.
Methods: In the study, 30 respiratory specimens positive for RSV were randomly selected from children with acute lower respiratory infections (ALRI) in Beijing every year from 2012 to 2021 for F gene sequencing. Then, 300 F gene sequences and 508 uploaded to GenBank from China were subjected to phylogenetic analysis.
Results: The results indicated the nucleotide identities were 95.4-100% among 446 sequences of RSV A, and 96.3-100% among 362 of RSV B. The most common variant loci were N80K (100.00%) and R213S (97.76%) for site Ø, and V384I/T (98.43%) for site I among sequences of RSV A, and M152I (100.00%), I185V (100.00%), and L172Q/H (94.48%) for site V, and R202Q (99.45%) for site Ø among sequences of RSV B. N276S appears in 95.29% sequences of RSV A, while S276N and N262 I/S appear in 1.38% and 0.55% sequences of RSV B, respectively. No variation was found in all sequences at the binding sites of 14N4 and motavizumab.
Conclusions: There were cumulative variations of the RSV F gene, especially at some binding sites of antigenic sites.
背景:呼吸道合胞病毒(RSV)主要抗原位点I-V和Ø的融合蛋白(F)的变异可能会影响RSV疫苗和疗法的开发:该研究从2012年至2021年每年从北京市急性下呼吸道感染(ALRI)患儿中随机抽取30份RSV阳性呼吸道标本进行F基因测序。然后,对中国300个F基因序列和508个上传到GenBank的F基因序列进行系统发育分析:结果表明,在 RSV A 的 446 条序列中,核苷酸同一性为 95.4%-100%;在 RSV B 的 362 条序列中,核苷酸同一性为 96.3%-100%;在 RSV A 的序列中,最常见的变异位点是位点Ø的 N80K(100.00%)和 R213S(97.76%)以及位点Ⅰ的 V384I/T(98.43%);在 RSV B 的序列中,最常见的变异位点是位点Ⅰ的 M152I(100.在 RSV B 的序列中,位点 V 为 M152I(100.00%)、I185V(100.00%)和 L172Q/H(94.48%),位点 Ø 为 R202Q(99.45%)。N276S 出现在 95.29% 的 RSV A 序列中,而 S276N 和 N262 I/S 分别出现在 1.38% 和 0.55% 的 RSV B 序列中。在 14N4 和莫他珠单抗结合位点的所有序列中均未发现变异:结论:RSV F 基因存在累积变异,尤其是在抗原位点的某些结合位点。
{"title":"The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China.","authors":"Fengjie Wang, Mingli Jiang, Zhenzhi Han, Yanpeng Xu, Yu Sun, Runan Zhu, Dongmei Chen, Qi Guo, Yutong Zhou, Yao Yao, Ling Cao, Dong Qu, Muya Li, Linqing Zhao","doi":"10.3390/idr16050081","DOIUrl":"https://doi.org/10.3390/idr16050081","url":null,"abstract":"<p><strong>Background: </strong>Variations in the fusion (F) protein of respiratory syncytial virus (RSV) with main antigenic sites I-V and Ø may affect the development of RSV vaccines and therapies.</p><p><strong>Methods: </strong>In the study, 30 respiratory specimens positive for RSV were randomly selected from children with acute lower respiratory infections (ALRI) in Beijing every year from 2012 to 2021 for <i>F</i> gene sequencing. Then, 300 <i>F</i> gene sequences and 508 uploaded to GenBank from China were subjected to phylogenetic analysis.</p><p><strong>Results: </strong>The results indicated the nucleotide identities were 95.4-100% among 446 sequences of RSV A, and 96.3-100% among 362 of RSV B. The most common variant loci were N80K (100.00%) and R213S (97.76%) for site Ø, and V384I/T (98.43%) for site I among sequences of RSV A, and M152I (100.00%), I185V (100.00%), and L172Q/H (94.48%) for site V, and R202Q (99.45%) for site Ø among sequences of RSV B. N276S appears in 95.29% sequences of RSV A, while S276N and N262 I/S appear in 1.38% and 0.55% sequences of RSV B, respectively. No variation was found in all sequences at the binding sites of 14N4 and motavizumab.</p><p><strong>Conclusions: </strong>There were cumulative variations of the RSV <i>F</i> gene, especially at some binding sites of antigenic sites.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"1017-1029"},"PeriodicalIF":3.4,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dana-Georgiana Nedelea, Diana Elena Vulpe, George Viscopoleanu, Alexandru Constantin Radulescu, Alexandra Ana Mihailescu, Sebastian Gradinaru, Mihnea Orghidan, Cristian Scheau, Romica Cergan, Serban Dragosloveanu
Objective: We present the case of a 26-year-old male with severe spinal tuberculosis of the thoracolumbar region. The patient suffered from worsening back pain over five years, initially responding to over-the-counter analgesics. Despite being proposed surgery in 2019, the patient refused the intervention and subsequently experienced significant disease progression.
Methods: Upon re-presentation in 2022, mild involvement of the T12-L1 vertebrae was recorded by imaging, leading to a percutaneous needle biopsy which confirmed tuberculosis. Despite undergoing anti-tuberculous therapy for one year, the follow-up in 2024 revealed extensive infection from T10 to S1, with large psoas abscesses and a pseudo-tumoral mass of the right thigh. The patient was ultimately submitted to a two-stage surgical intervention: anterior resection and reconstruction of T11-L1 with an expandable cage, followed by posterior stabilization from T8-S1.
Results: Postoperative recovery was uneventful, with significant pain relief and no neurological deficits. The patient was discharged on a continued anti-tuberculous regimen and remains under close surveillance.
Conclusions: This paper presents details on the challenges of diagnosis and management of severe spinal tuberculosis, with emphasis on the importance of timely intervention and multidisciplinary care.
{"title":"Progressive Thoracolumbar Tuberculosis in a Young Male: Diagnostic, Therapeutic, and Surgical Insights.","authors":"Dana-Georgiana Nedelea, Diana Elena Vulpe, George Viscopoleanu, Alexandru Constantin Radulescu, Alexandra Ana Mihailescu, Sebastian Gradinaru, Mihnea Orghidan, Cristian Scheau, Romica Cergan, Serban Dragosloveanu","doi":"10.3390/idr16050080","DOIUrl":"https://doi.org/10.3390/idr16050080","url":null,"abstract":"<p><strong>Objective: </strong>We present the case of a 26-year-old male with severe spinal tuberculosis of the thoracolumbar region. The patient suffered from worsening back pain over five years, initially responding to over-the-counter analgesics. Despite being proposed surgery in 2019, the patient refused the intervention and subsequently experienced significant disease progression.</p><p><strong>Methods: </strong>Upon re-presentation in 2022, mild involvement of the T12-L1 vertebrae was recorded by imaging, leading to a percutaneous needle biopsy which confirmed tuberculosis. Despite undergoing anti-tuberculous therapy for one year, the follow-up in 2024 revealed extensive infection from T10 to S1, with large psoas abscesses and a pseudo-tumoral mass of the right thigh. The patient was ultimately submitted to a two-stage surgical intervention: anterior resection and reconstruction of T11-L1 with an expandable cage, followed by posterior stabilization from T8-S1.</p><p><strong>Results: </strong>Postoperative recovery was uneventful, with significant pain relief and no neurological deficits. The patient was discharged on a continued anti-tuberculous regimen and remains under close surveillance.</p><p><strong>Conclusions: </strong>This paper presents details on the challenges of diagnosis and management of severe spinal tuberculosis, with emphasis on the importance of timely intervention and multidisciplinary care.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"1005-1016"},"PeriodicalIF":3.4,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sevim Mese, Aytaj Allahverdiyeva, Mustafa Onel, Hayriye Kırkoyun Uysal, Ali Agacfidan
Aim: Respiratory viruses significantly impact public health, contributing to high morbidity and mortality rates in both children and adults. This study evaluates the distribution and incidence of respiratory tract viruses in our hospital from 2019 to 2022, focusing on changes post-COVID-19 pandemic. Material and Methods: Utilizing molecular methods, we analyzed nasopharyngeal swabs with the FTD Respiratory Pathogens 21 kit and the QIAStat Dx Respiratory Panel kit at Istanbul Faculty of Medicine. A total of 1186 viruses were detected in 2488 samples (47.6% of the total) examined with the FTD Respiratory Pathogens 21 kit between 2019 and 2022. Results: It was determined that the detection rates were 52.8% in 2019, 44.3% in 2020, 50.0% in 2021, and 40.0% in 2022. Notable changes in prevalence were observed for pandemic influenza A (IAV-H1N1pdm2009), parainfluenza virus (PIV)-3, rhinovirus (RV), and respiratory syncytial virus (RSV)-A/B (p < 0.05). RV consistently showed the highest detection rates across all years (17.6% to 7.9%). Additionally, 1276 viruses were detected in 1496 samples using the QIAStat DX kit, with 91.3% positivity in 2021 and 78.6% in 2022, highlighting the kit's effectiveness in rapid diagnosis. Conclusions: This study enhances understanding of respiratory virus epidemiology during and after the pandemic, emphasizing the need for ongoing surveillance and strategic public health measures to address the evolving landscape of respiratory infections.
{"title":"Investigation of the Effect of the COVID-19 Pandemic Period on Respiratory Tract Viruses at Istanbul Medical Faculty Hospital, Turkey.","authors":"Sevim Mese, Aytaj Allahverdiyeva, Mustafa Onel, Hayriye Kırkoyun Uysal, Ali Agacfidan","doi":"10.3390/idr16050079","DOIUrl":"https://doi.org/10.3390/idr16050079","url":null,"abstract":"<p><p><b>Aim:</b> Respiratory viruses significantly impact public health, contributing to high morbidity and mortality rates in both children and adults. This study evaluates the distribution and incidence of respiratory tract viruses in our hospital from 2019 to 2022, focusing on changes post-COVID-19 pandemic. <b>Material and Methods:</b> Utilizing molecular methods, we analyzed nasopharyngeal swabs with the FTD Respiratory Pathogens 21 kit and the QIAStat Dx Respiratory Panel kit at Istanbul Faculty of Medicine. A total of 1186 viruses were detected in 2488 samples (47.6% of the total) examined with the FTD Respiratory Pathogens 21 kit between 2019 and 2022. <b>Results:</b> It was determined that the detection rates were 52.8% in 2019, 44.3% in 2020, 50.0% in 2021, and 40.0% in 2022. Notable changes in prevalence were observed for pandemic influenza A (IAV-H1N1pdm2009), parainfluenza virus (PIV)-3, rhinovirus (RV), and respiratory syncytial virus (RSV)-A/B (<i>p</i> < 0.05). RV consistently showed the highest detection rates across all years (17.6% to 7.9%). Additionally, 1276 viruses were detected in 1496 samples using the QIAStat DX kit, with 91.3% positivity in 2021 and 78.6% in 2022, highlighting the kit's effectiveness in rapid diagnosis. <b>Conclusions:</b> This study enhances understanding of respiratory virus epidemiology during and after the pandemic, emphasizing the need for ongoing surveillance and strategic public health measures to address the evolving landscape of respiratory infections.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"992-1004"},"PeriodicalIF":3.4,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nathalia Lopez Duarte, Ana Paula Silva Bueno, Bárbara Sarni Sanches, Gabriella Alves Ramos, Layanara Albino Batista, Thalita Fernandes de Abreu, Marcelo Gerardin Poirot Land, Cristiane Bedran Milito
Malignant lymphoma is an unusual form of gallbladder neoplasm. Almost all these tumors are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type lymphomas. Herein, we present a literature review of gallbladder Burkitt's lymphoma (BL) cases that includes also an unpublished case in an HIV-infected child, observed by our center. The patient (a five-year-old black female child) attended the Federal Hospital of Lagoa, Rio de Janeiro, Brazil, underwent cholecystectomy, and the postoperative pathological analysis of the gallbladder revealed a diagnosis of BL (EBV-positive). Also, HIV serology was performed and returned positive. She was transferred to the Martagão Gesteira Institute of Pediatrics and Childcare for oncological treatment, dying from sepsis and disease progression about 18 months later. The patient did not undergo ART/cART. Previous cases of gallbladder BL were herein described and analyzed to characterize the clinicopathological features and possible similarities. BL can occur in the gallbladder both in the context of HIV infection and in the pediatric population. A biopsy is mandatory in cases with suggestive findings of lymphoma, and an early diagnosis can change the course of the disease. Furthermore, the case highlights the importance of an early initiation of ART/cART in people living with HIV (PLWH), especially in children.
恶性淋巴瘤是一种不常见的胆囊肿瘤。这些肿瘤几乎都是弥漫大B细胞淋巴瘤或粘膜相关淋巴组织型淋巴瘤。在此,我们对胆囊伯基特淋巴瘤(BL)病例进行了文献综述,其中还包括本中心观察到的一例未发表的 HIV 感染儿童病例。患者(一名五岁的黑人女性儿童)在巴西里约热内卢的拉戈阿联邦医院接受了胆囊切除术,术后胆囊病理分析显示诊断为BL(EBV阳性)。此外,还进行了艾滋病毒血清学检查,结果呈阳性。她被转到马尔塔甘-盖斯提拉儿科和儿童保健研究所(Martagão Gesteira Institute of Pediatrics and Childcare)接受肿瘤治疗,约18个月后死于败血症和疾病进展。患者没有接受抗逆转录病毒疗法/卡介苗治疗。本文对以往的胆囊癌病例进行了描述和分析,以确定其临床病理特征和可能的相似之处。胆囊炎既可发生在艾滋病病毒感染者中,也可发生在儿童人群中。对于提示淋巴瘤的病例,必须进行活检,早期诊断可改变病程。此外,该病例还强调了对艾滋病病毒感染者(PLWH),尤其是儿童及早开始抗逆转录病毒疗法(ART)/抗逆转录病毒疗法(cART)的重要性。
{"title":"Gallbladder Burkitt's Lymphoma: A Literature Review Including a Case Report in a Child Living with HIV.","authors":"Nathalia Lopez Duarte, Ana Paula Silva Bueno, Bárbara Sarni Sanches, Gabriella Alves Ramos, Layanara Albino Batista, Thalita Fernandes de Abreu, Marcelo Gerardin Poirot Land, Cristiane Bedran Milito","doi":"10.3390/idr16050078","DOIUrl":"https://doi.org/10.3390/idr16050078","url":null,"abstract":"<p><p>Malignant lymphoma is an unusual form of gallbladder neoplasm. Almost all these tumors are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type lymphomas. Herein, we present a literature review of gallbladder Burkitt's lymphoma (BL) cases that includes also an unpublished case in an HIV-infected child, observed by our center. The patient (a five-year-old black female child) attended the Federal Hospital of Lagoa, Rio de Janeiro, Brazil, underwent cholecystectomy, and the postoperative pathological analysis of the gallbladder revealed a diagnosis of BL (EBV-positive). Also, HIV serology was performed and returned positive. She was transferred to the Martagão Gesteira Institute of Pediatrics and Childcare for oncological treatment, dying from sepsis and disease progression about 18 months later. The patient did not undergo ART/cART. Previous cases of gallbladder BL were herein described and analyzed to characterize the clinicopathological features and possible similarities. BL can occur in the gallbladder both in the context of HIV infection and in the pediatric population. A biopsy is mandatory in cases with suggestive findings of lymphoma, and an early diagnosis can change the course of the disease. Furthermore, the case highlights the importance of an early initiation of ART/cART in people living with HIV (PLWH), especially in children.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"981-991"},"PeriodicalIF":3.4,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In July 2024, poliovirus was identified in Gaza, prompting the World Health Organization (WHO) to issue a warning regarding the potential for polio to spread in the region [...].
{"title":"The Battle beyond the Battlefield: War's Influence on Antibiotic Resistance.","authors":"Guido Granata, Stefania Cicalini, Nicola Petrosillo","doi":"10.3390/idr16050077","DOIUrl":"https://doi.org/10.3390/idr16050077","url":null,"abstract":"<p><p>In July 2024, poliovirus was identified in Gaza, prompting the World Health Organization (WHO) to issue a warning regarding the potential for polio to spread in the region [...].</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"977-980"},"PeriodicalIF":3.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Invasive fungal infections affecting the central nervous system (CNS) are a major health concern worldwide associated with high mortality rates. Their increased incidence is largely due to an increase in the vulnerable immunocompromised population, changing environmental factors, and development of more accurate diagnostic methods. The aim of this article is to identify fungal causes of CNS infections that are recently emerging or have the potential to become emerging pathogens in the near future, as well as their clinical characteristics, including: Candida auris, Trichosporon spp., Blastomyces spp., Sporothrix spp., Talaromyces marneffei, Lomentospora prolificans, and Scedosporium spp.
Methods: A review of the literature in PubMed in the last ten years was conducted to identify central nervous system infections caused by each of these fungi.
Results: The review identified 10 cases caused by C. auris, 5 cases by Trichosporon spp., 82 cases by Blastomyces spp., 36 cases by Sporothrix spp., 21 cases by T. marneffei, 22 cases by Lomentospora prolificans, and 42 cases by Scedosporium spp.
Discussion: The exact burden of these diseases remains difficult to ascertain, but their apparent rise underscores the urgent need for improved diagnostic, treatment, and management strategies against CNS fungal pathogens to improve outcomes against these life-threatening infections.
{"title":"Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review.","authors":"Rita Lino, André Rodrigues Guimarães, Estela Sousa, Mariana Azevedo, Lurdes Santos","doi":"10.3390/idr16050076","DOIUrl":"https://doi.org/10.3390/idr16050076","url":null,"abstract":"<p><strong>Introduction: </strong>Invasive fungal infections affecting the central nervous system (CNS) are a major health concern worldwide associated with high mortality rates. Their increased incidence is largely due to an increase in the vulnerable immunocompromised population, changing environmental factors, and development of more accurate diagnostic methods. The aim of this article is to identify fungal causes of CNS infections that are recently emerging or have the potential to become emerging pathogens in the near future, as well as their clinical characteristics, including: <i>Candida auris</i>, <i>Trichosporon</i> spp., <i>Blastomyces</i> spp., <i>Sporothrix</i> spp., <i>Talaromyces marneffei</i>, <i>Lomentospora prolificans</i>, and <i>Scedosporium</i> spp.</p><p><strong>Methods: </strong>A review of the literature in PubMed in the last ten years was conducted to identify central nervous system infections caused by each of these fungi.</p><p><strong>Results: </strong>The review identified 10 cases caused by <i>C. auris</i>, 5 cases by <i>Trichosporon</i> spp., 82 cases by <i>Blastomyces</i> spp., 36 cases by <i>Sporothrix</i> spp., 21 cases by <i>T. marneffei</i>, 22 cases by <i>Lomentospora prolificans,</i> and 42 cases by <i>Scedosporium</i> spp.</p><p><strong>Discussion: </strong>The exact burden of these diseases remains difficult to ascertain, but their apparent rise underscores the urgent need for improved diagnostic, treatment, and management strategies against CNS fungal pathogens to improve outcomes against these life-threatening infections.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"16 5","pages":"952-976"},"PeriodicalIF":3.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}